key: cord-0925756-vh6hc9fm
authors: SINGH, A. K.; Phatak, S. R.; Singh, R.; Bhattacharjee, K.; Singh, N. K.; Gupta, A.; Sharma, A.
title: Humoral Antibody Kinetics with ChAdOx1-nCOV (CovishieldTM) and BBV-152 (CovaxinTM) Vaccine among Indian Healthcare workers: A 6-month Longitudinal Cross-sectional Coronavirus Vaccine-induced Antibody Titre (COVAT) Study
date: 2022-02-05
journal: nan
DOI: 10.1101/2022.02.03.22270182
sha: 46fbb453d02f6c47df0e6e14bf9b31800df5d806
doc_id: 925756
cord_uid: vh6hc9fm

Background and Aims: There is limited data available on longitudinal humoral antibody dynamics following two doses of ChAdOx1-nCOV (CovishieldTM) and BBV-152 (CovaxinTM) vaccine against SARS-CoV-2 among Indians. Methods: We conducted a 6-month longitudinal study in vaccinated healthcare workers by serially measuring quantitative anti-spike antibody at 3-weeks, 3-months and 6-months after the completion of second dose. Geometric mean titer (GMT) and linear mixed models were used to assess the dynamics of antibody levels at 6 months. Results: Of the 481 participants, GMT of anti-spike antibody decreased by 56% at 6-months regardless of demographics and comorbidities in 360 SARS-CoV-2 naive individuals, significantly in hypertensives. Participants with past infection had significantly higher GMT at all time points compared to naive individuals. Among SARS-CoV-2 naive cohorts, a significantly higher GMT was noted amongst the Covishield recipients at all time points, but there was a 44% decline in GMT at 6-month compared to peak titer period. Decline in GMT was insignificant (8%) in Covaxin recipients at 6-month despite a lower GMT at all time points vs. Covishield. There was 5.6-fold decrease in seropositivity rate at 6-month with both vaccines. Participants with type 2 diabetes mellitus have a lower seropositivity rate at all the time points. While seropositivity rate was significantly higher with Covishield vs. Covaxin at all time points except at 6-month where Covaxin recipients had a higher seropositivity, although no difference in seropositivity was noted in propensity-matched analysis. Conclusions: There is waning humoral antibody response following two doses of either vaccine at six months.

Available phase 3 randomized clinical trials (RCTs) of both vaccines found them safe and significantly effective [1, 2] . However, there is still a paucity of data in the real-world settings as to how much and how long both these novel vaccines can elicit an immune response both at humoral and cellular level. Long-term antibody kinetics after the completion of both doses of Covishield and Covaxin in Indians is even less well known. We have recently reported the short-term anti-spike antibody humoral response after the first and second dose of both vaccines from Cross-sectional Coronavirus Vaccine-induced Antibody Titre (COVAT) study [3] .

Here, we report a longitudinal 6-month follow-up of humoral antibody kinetics from COVAT study after the completion of the second dose.

Our report follows the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline for cross-sectional studies [4] .

COVAT study was a pan-India, cross-sectional study approved by the ethical committee of Thakershy Charitable Trust, Ahmedabad, Gujarat, India. Informed consent was taken on Google-sheet from all the participants who volunteered to participate in this study. Inclusion and exclusion criteria for this study has already been published earlier [3] . Summarily, all adult health care workers (HCWs) of >18 years of age who completed two dose of either vaccine and had completed a total of four measured anti-spike antibody titre until 6-month of second dose were included in this analysis. Measurement of anti-spike antibody at four time-points include -a. first sample: day 21 after the first dose until the day before the second dose, b. second sample: day 21-28 of second dose, c. third sample: day 83-97 (3months) of second-dose and, d. fourth sample: day 173-187 (6-months) after the second dose. An additional 7 days for collection of blood samples was allowed due to sporadic lockdown at that point of time. Participants who had past (recovered from the COVID-19 >6 weeks before the first dose of either vaccine)

were also included in this study. Participants who acquired confirmed SARS-CoV-spike antibody kinetics over the 6-month period after receipt of the second vaccine dose and to associate these changes with the demographic characteristics and coexisting conditions of the study participants. The dependent variable was first logtransformed. The covariates in the linear mixed model analysis included sex, age group (< 60 years and > 60 years), body-mass index (BMI; the weight in kilograms divided by the square of the height in meters), co-existing co-morbid conditions, diabetes status, duration of diabetes, hypertension status, duration of hypertension, dyslipidemia, ischemic heart disease, type of vaccine etc. Time was modeled as a linear trend from the receipt of the second dose up to 6 months. The estimated effects of covariates are presented as ratios of means with 95% confidence intervals on the original logarithmic scale of the anti-spike antibodies. Cochran's Q test is used to determine if there are differences on a dichotomous dependent variable i.e., the seropositivity rate (defined as yes or no) between different time points of antibody titer measurement after second dose of vaccination. Repeated measures ANOVA with post-hoc adjustment method is used to evaluate for any significant differences in antibody titer measurements between different time points within similar cohort. We took into account both Greenhouse Geiser correction and Huynh-Feldt correction, in case the assumption of sphericity was violated by Mauchly's test of sphericity. One-way ANOVA (analysis of variance) with post-hoc test has been used to find the significance of study parameters between three cohort of patients viz. SARS-CoV-2 naïve, breakthrough infection and past infection. A propensity score was generated taking into consideration age, sex and BMI of the SARS-CoV-2 naive cohorts after two complete doses of either vaccine to eliminate the bias that could have creeped in due to the convenience sampling method. Multiple binary logistic regression analysis was carried out to identify the independent predictors of breakthrough infection. A two-sided p value of less than 0.05 was considered to indicate statistical significance. Entire . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 

As mentioned in methodology, a linear mixed model was fitted to examine the anti-spike antibody kinetics over the 6-month period (time was modeled as a linear trend) in SARS-CoV-2 naive individuals (N = 360) to study the change with the demographic characteristics and with associated co-morbidities of the study participants. Our analysis found that in the peak periods (defined as day 21 through . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted February 5, 2022. ;

28 after the receipt of second dose of vaccine) a significantly lower anti-spike antibody titers was associated with participants with age >60 years and participants having any co-morbidities compared to age ≤ 60 years and individuals without comorbidities, but no such difference was noted at the end-of-study period (defined as day 180 through 187 after receipt of the second dose). There was no difference noted in the anti-spike antibody titers at the peak and at the end-of-study period with regard to gender, body-mass index and blood group. While no significant difference in antibody titre was noted in participants with T2DM, dyslipidemia, ischemic heart disease vs. without these comorbidities, a significantly lower antispike antibody titer was seen in the hypertensive subjects at the end of study period (but not in the peak period). Notably, while a higher anti-spike antibody titer was noted amongst the Covishield recipients at the peak titer period (factor 1.62; 95% CI, 1.15-2.26), this was no longer significant at the end-of-study period (factor 1.37; 95% CI, 0.77-1.59). Similar findings were noted in the mixed model analysis of propensity matched (age, Sex and BMI) cohorts (n = 41, in each group) who took either Covishield or Covaxin. Propensity matched analysis found a significantly higher anti-spike antibody titre amongst the Covishield recipients during the peak period (factor 1.72; 95% CI, 1.18-2.63) compared to Covaxin but not at the end-of-study period (factor 1.46; 95% CI, 0.83-1.67). Table 1 summarizes the findings from mixed model analysis.

Collectively, there was a trend of decline in antibody titre in all participants over time but it was significantly lower at the end of 6-months in hypertensive vs. normotensive participants.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted February 5, 2022.

A significant difference (p <0.001) in the geometric mean antibody titre was noted between the participants who were SARS-CoV-2 naive, had breakthrough infection and with a past history of COVID-19 during all the sampling time points as computed by one-way ANOVA test. Amongst all fully vaccinated cohorts, there was a significantly lower GMT in SARS-CoV-2 naive participants at 3-and 6month (GMT 67.83 AU/mL; 95% CI, 67.24-68. 15 and breakthrough infection both at 3-month (p = 0.397) and 6-month (p = 0.369) after the second dose. When we analysed the trend in antibody titre for withingroup difference across various time points by repeated measures ANOVA, we found a significant increase in GMT in SARS-CoV-2 naive cohort at 21-days and 3-months after the second dose (both p <0.001) but the GMT returned to the baseline value (titre at 21-days after the first dose) at 6-months (p = 0.177). In the breakthrough infection cohort, the GMT increased significantly across all the subsequent sampling (21-days and 3-months post-second dose, both p <0.001), however there was a significant (p <0.001) dip in the antibody titre at 6-months after second dose. For the participants with past history of COVID-19, there was a nominally significant increase in GMT at 21-days after second dose (p = 0.049) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted February 5, 2022. ; compared to 21-days after first dose (baseline value), and no significant difference noted compared to baseline value at 3-months (p = 0.26) and 6-months (p = 0.15) after the second dose. Overall, there was 41% decline in anti-spike GMT at 6month compared to peak period (21-days after the second dose) in all 481 participants. In SARS-CoV-2 naive individuals, anti-spike GMT decreased by 56% at 6-month compared to the peak period. Comparatively, anti-spike antibody GMT was significantly higher at all time points in Covishield recipients compared to Covaxin recipients, including at 6-months following second dose. Interestingly, while there was a significant 44% decline in the anti-spike antibody GMT in Covishield recipients at 6-months compared to the peak period (21-days after the second dose), no significant (8%) decline in antispike GMT was observed in Covaxin recipients at 6-months. This finding is unique Table   2 summarizes the findings between the three groups.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 5, 2022. ;

Collectively, these findings suggest a greater antibody response following vaccination in those who had SARS-CoV-2 infection either before the first dose or after the second dose compared to infection naive individuals, which is an expected finding. Importantly, this longitudinal study also showed that anti-spike antibody decreased by 56% at 6-months as compared to the peak period in SARS-COV-2 naive cohorts. Despite a significantly greater GMT of anti-spike antibody in Covishield recipients at all time point compared to Covaxin in SARS-CoV-2 naive cohorts, there was a significant 44% decline in anti-spike antibody in the former group compared to the later (nonsignificant 8%). And, a similar significant decline (45%) with Covishield while no apparent decline (11%) with Covaxin was also noted in propensity matched (N =41, in each arm) SARS-CoV-2 naive cohorts.

Overall, there was a significant (5.6-fold) decline in the seropositivity rate over a period of six months after the second dose in SARS-CoV-2 naive cohort.

Reduction in seropositivity at the 6-month was noted in relation to all the studied clinical demographic parameters (p <0.001) regardless of the type of vaccine received. The seropositivity rate in the age group ≤ 60 years is significantly higher at all the time points compared to the age >60 years. Similarly, participants with T2DM have a lower seropositivity rate at all the time points compared to those without. No difference in seropositivity was noted at any of the time points with regard to gender, BMI, blood group, presence or absence of HTN (including its duration), dyslipidemia and IHD. Although Covishield recipients have higher seropositivity rate both at 21-days and 3-months after the second dose, a significantly (P = 0.009) higher seropositivity rate in Covaxin recipients (38%) was noted at six months compared to Covishield recipient (22%). However, in the . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 5, 2022. ;

propensity-matched analysis there was no significant (p = 0.24) difference in seropositivity rate at 6-months between the two vaccines. Table 3 summarizes the findings on trend of seropositivity rate in SARS-CoV-2 naive individuals.

Overall, in the span of 6-months, 64 participants had breakthrough infections 

In this cross-sectional longitudinal study, there was a significant waning of humoral response within 6 months after receipt of the second dose of both Covishield and Covaxin vaccine in 360 SARS-CoV-2 naive cohort of HCWs, regardless of age, sex, BMI and comorbidities. While we observed a 56% decrease in anti-spike antibody GMT at 6-month after an initial peak following completion of second dose, hypertensive cohorts had significantly less GMT at all time points vs. normotensive participants. Similarly, people with T2DM had significantly less seropositivity to anti-spike antibody at all time points. Our findings are in concordance to several other studies conducted with different vaccines . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. anti-spike antibody compared to the first dose [17] . We also demonstrated that despite a significant increase in anti-spike antibody GMT with Covishield at all . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 5, 2022. ; time points (21-days post-first dose to 6-month post-second dose) compared to Covaxin, there was a 44% decline in GMT over 6 months from the initial peak (21days post first dose) in Covishield recipients. However, in Covaxin recipients antispike antibody GMT was relatively stable over the 6-months with minimal-to-no (8%) decline despite a modest rise in anti-spike GMT at all time points. Our finding is in contrary to the only other longitudinal study of Covaxin in Indian HCWs that found a 4-fold decrease in median anti-spike antibody titer at 6-month whilst Covishield recipient had only 2-fold decline despite a significantly higher median antibody titer with Covishield at all time points vs. Covaxin [11] . As mentioned earlier, other Indian study reported a 72% decay rate in antibody titre at 6-month in Covishield recipient [10] . The reason for this discrepancy of slow decay of antibody with Covaxin in our study is not exactly known and needs to be studied, however, however at least one comparative Indian study found Covaxin generating better cell-mediated immunity compared to Covishield whilst Covishield was more effective in inducing humoral immunity compared to Covaxin [18] . To the best of our knowledge, this Pan-India cross-sectional COVAT study would be the first of its kind that has involved HCWs from 13 States and 22 cities and reporting a longitudinal anti-spike antibody kinetics 6-month after the second dose of two different vaccines in three different groups of participants-that include individuals who remained SARS-CoV-2 naive, participants with breakthrough infections and people who had past history of COVID-19 before the first dose of vaccine. However, we do acknowledge several limitations. First, we have used a convenience sampling in the present study which amounts to selection bias. Second, our study had all health care workers, mostly healthy persons and therefore they may not represent the general population. Third, we did not have dilution and neat values for those sample that hit both the upper and lower limit of kit value that assessed anti-spike antibody. This could have likely underestimated the GMT in those recipients who had undiluted plateaued value. Fourth, using the mixed model linear analysis may lead to loss in power to detect the significant difference due to double fitting of the study parameter. Fifth, we used a binary logistic regression to identify the independent predictors of breakthrough infection but this model may miss out any predictor variable which may have non-linear relationship with the outcome variable. Lastly, we have measured only anti-spike . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 5, 2022. ;

binding antibody and could not assess NAb and cell-mediated immune response such as Th-1 and Th-2 dependent antibody or cytokines (primarily due to the lack of standardized commercial labs in India). Although a high correlation with spike protein-based ELISA and different antibody classes to NAb have been documented recently [27] . Finally, because of logistic issues (due to lockdown) during pandemic we could not measure the baseline anti-spike antibody titre prior to the first dose of vaccine.

In conclusion, this cross-sectional 6-month longitudinal study found-a) Waning of anti-spike antibody titre over time regardless of age, sex, BMI, comorbidities and type of vaccine but it was significantly low in hypertensive cohort vs. normotensive at 6-month, b) Participants with past history of COVID-19 had significantly higher anti-spike antibody titer at all time points compared to SARS-CoV-2 naive individuals after two doses of either vaccine, c) Second dose of vaccine did only a little augmentation of spike antibody titre compared to the first dose, d) Covishield recipients had significantly higher anti-spike antibody titer at all time points until 6-month after two doses, e) There was a 56% decline in antispike antibody GMT at 6-months compared to the peak period (21-days after second dose) in SARS-CoV-2 naive individuals, f) There was a 44% decline in anti-spike antibody GMT at 6-months compared to peak period (at 21-days) after the second dose of Covishield, g) There was minimal-to-no reduction (8% decline) in anti-spike antibody GMT at 6-months compared to peak period (at 21-days) after the second dose of Covaxin and similar findings were noted in propensitymatched cohorts, h) There was 5.6-fold reduction in seropositivity to anti-spike antibody at 6-month in SARS-CoV-2 naive cohorts regardless of the vaccine received, i) Despite a significant decline in seropositivity with both vaccines, . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 5, 2022. ; seropositivity was significantly higher with Covaxin compared to Covishield at 6month in SARS-CoV-2 naive cohorts, although no significant difference was noted in propensity-matched cohorts, j) No significant difference in breakthrough infection rate was noted between Covishield and Covaxin recipients at 6-month.

We would like to thank all the participants who volunteered for this study. We express our sincere gratitude and acknowledgment to our Indian regional coordinators for the smooth conduct of this study that include (in alphabetical 

AKS and SRP conceptualized, and designed the study. NKS, AG and AS monitored the study and captured the data at all points of time. AKS, KB, AS and RS conducted the statistical analysis. AKS and RS wrote the first draft. AKS, KB . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 5, 2022. ;

and RS revised the manuscript. All authors gave their intellectual inputs while preparing the manuscript and agreed mutually to submit to this journal.

No funding received for this cross-sectional study.

Authors have no competing interest to declare.

All the authors are responsible for the originality of this study. Original data can be shared from first author, if necessary, after a reasonable request. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 5, 2022. ; is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 5, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 5, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 5, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 5, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 5, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 5, 2022. 

BBV-152 and AZD1222 Vaccines

Months after the Second Dose of mRNA-1273 Vaccine for Covid-19

Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination

Differential Kinetics of Immune Responses Elicited by Covid-19 Vaccines

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

Kinetics and correlates of the neutralizing antibody response to SARSCoV-2 infection in humans

Immunity to COVID-19 in India through vaccination and natural infection. medRxiv preprint

Severe acute respiratory syndrome coronavirus 2; RAS: Renin angiotensin system